SHH and neoplasm: To test SigPath in primary human tumor samples, we applied the IMAC portion of the assay (Dataset EV1) to brain tissue specimens from 39/40 medulloblastoma patients representing all established subgroups (WNT, SHH, Gr3, and Gr4), previously analyzed by deepscale proteomics, phosphoproteomics (including IMAC and pY enrichment), and acetylproteomics (Archer et al, 2018; Fig EV4A).